Recently, 2 independent groups demonstrated that anti-HNA-3a reacted with the Arg 154 isoform, whereas anti-HNA-3b recognized the Glu 154 isoform of the choline transporter-like protein 2 (CTL2; also known as SLC44A2). 12,14 By the use Objective-Antibodies against human neutrophil antigen-3a (HNA-3a) located on choline transporter-like protein 2 induce severe transfusion-related acute lung injury (TRALI). This study aims to identify the mechanism implicated in anti-HNA-3a-mediated TRALI. Approach and Results-Our analysis shows that anti-HNA-3a recognizes 2 choline transporter-like protein 2 isoforms (P1 and P2) on human microvascular endothelial cells from lung blood vessels but reacts only with the P1 isoform on neutrophils. Direct treatment of HNA-3a-positive endothelial cells with anti-HNA-3a, but not with anti-HNA-3b, leads to reactive oxygen species production, increased albumin influx, and decreased endothelial resistance associated with the formation of actin stress filaments and loosening of junctional vascular endothelium-cadherin. In a novel in vivo mouse model, TRALI was documented by significant increase in lung water content, albumin concentration, and neutrophil numbers in the bronchoalveolar lavage on injection of human anti-HNA-3a in lipopolysaccharides-treated, as well as nontreated mice. Interestingly, although neutrophil depletion alleviated severity of lung injury, it failed to prevent TRALI in this model. Infusion of anti-HNA-3a F(ab′) 2 fragments caused moderate TRALI. Finally, mice lacking nicotinamide adenine dinucleotide phosphate oxidase (NOX2 y/-) were protected from anti-HNA-3a-mediated TRALI. Conclusions-These data demonstrate the initiation of endothelial barrier dysfunction in vitro and in vivo by direct binding of anti-HNA-3a on endothelial cells. It seems, however, that the presence of neutrophils aggravates barrier dysfunction. This novel mechanism of TRALI primarily mediated by endothelial cell dysfunction via choline transporter-like protein 2 may help to define new treatment strategies to decrease TRALI-related mortality. (Arterioscler Thromb Vasc Biol. 2013;33:2538-2548.)
T ransfusion-related acute lung injury (TRALI) is a serious, often life-threatening pulmonary transfusion reaction characterized by noncardiogenic lung edema, hypoxemia, and respiratory distress in temporal association with blood transfusion. 1 Today, TRALI is the leading cause of transfusion-related mortality in developed countries. [2] [3] [4] Since the first description of TRALI, the presence of antibodies against human leukocytes in the transfused blood component has been implicated as a major mediator of TRALI. [5] [6] [7] The cognate antigens for these antibodies are either human leukocyte antigens (HLA) class I and class II or human neutrophil antigens (HNAs) expressed on the recipient's white blood cells. The interaction between the antibody and its cognate antigen is thought to induce neutrophil activation, sequestration, and, finally, endothelial barrier damage. 8 Recent studies showed that anti-HNA-3a seems to cause fatal TRALI more often than other neutrophil-reactive antibodies. 9, 10 Contrary observations, however, were also reported. 11 Anti-HNA-3a antibodies are known to induce large neutrophil aggregates in vitro via an Fc-independent mechanism. 12 Such cell aggregates could accumulate in precapillary pulmonary vessels promoting severe lung edema as observed in patients with TRALI. In addition, Silliman et al 13 could demonstrate in a 2-hit model that primed neutrophils incubated with anti-HNA-3a were able to induce damage of human pulmonary microvascular endothelial cells in vitro via neutrophil-derived reactive oxygen species (ROS) production. The exact mechanism, however, remains elusive. of expression studies in mammalian cells, we could recently demonstrate that this single point mutation Arg 154 Glu is indeed responsible for the formation of HNA-3 antigenic determinants. 15 The target antigen HNA-3a is a high-frequency antigen with phenotype frequencies of 0.792 and 0.738 in white and Asian populations, respectively. 16 CTL2 is a multiple membrane-spanning glycoprotein, which is not only expressed on white blood cells but also on different tissues, including lung. CTL2 exists in 2 different isoforms, CTL2-P1 and CTL2-P2, which show variable distribution patterns among different cells. 17 Recent studies demonstrated that only CTL2-P2 has choline transporter activity in lung epithelial cells. 18 On the basis of previous observation demonstrating that CTL2 is highly expressed in lung tissue and the well-known fact that ligation of antigens on endothelial cells by antibodies could lead to cellular stimulation, 19 we sought to analyze whether anti-HNA-3a may initiate TRALI by direct functional action on pulmonary endothelial cells.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Endothelial Cells Express P1 and P2 Isoforms of CTL2 and React With Anti-HNA-3a
Recently, the presence of 2 different mRNA transcripts encoding for P1 and P2 isoforms of CTL2 (termed CTL2-P1 and CTL2-P2) in mouse lung tissue was demonstrated. 17 CTL2-P1 and CTL2-P2 differ in the first exon (exon 1a or exon 1b) that encodes for 10 to 12 amino acids ( Figure 1A , left). To analyze the presence of human CTL2-P1 and CTL2-P2 transcripts in endothelial cells and neutrophils, reverse transcription-polymerase chain reaction was established using specific forward primers, P1 or P2, and a universal reverse primer. As shown in Figure 1A (right), CTL2-P1 (350 bp) and CTL2-P2 (450 bp) could be detected in human microvascular endothelial cells derived from lung blood vessels (HMVEC-L) and in human umbilical vein endothelial cells (HUVEC), whereas neutrophils carry the CTL2-P1 isoform only. Subsequently, neutrophils and endothelial cells were typed for the presence of HNA-3a and HNA-3b alleles by polymerase chain reaction-sequence-specific primers 15 and tested with anti-HNA-3a or anti-HNA-3b by flow cytometry ( Figure 1B ). Homozygous HNA-3aa endothelial cells and neutrophils reacted with anti-HNA-3a but not with anti-HNA-3b antibodies. Comparison of mean fluorescence intensity values showed that both endothelial cells, HUVEC and HMVEC-L, carry more binding sites for anti-HNA-3a than that of the neutrophils (mean fluorescence intensity, 59.2±7.1 and 62.1±3.4 versus 24.7±3. 8; n=3 ). To answer the question whether anti-HNA-3a may react with either CTL2 isoforms, stably transfected human embryonic kidney (HEK) cells expressing either CTL2-P1 (P1-HEK) or CTL2-P2 (P2-HEK) were generated ( Figure 1B ). Testing of different anti-HNA-3a antibodies (n=4) showed positive reactions with both transfected cells indicating that anti-HNA-3a antibodies recognize CTL2-P1 and CTL2-P2. These results may explain the strong reactivity of anti-HNA-3a antibodies with endothelial cells compared with neutrophils. Immunostaining of HMVEC-L and HUVEC with purified anti-HNA-3a antibodies confirmed the specific expression of CTL2 on both the cells ( Figure 1C ).
Anti-HNA-3a Antibodies Decrease Transendothelial Electric Resistance
To investigate the functional effect of anti-HNA-3a binding on endothelial cells, transendothelial electric resistance was measured in real time. Similar to endothelial treatment with thrombin (1 U/mL), treatment of HNA-3aa homozygous HMVEC-L with anti-HNA-3a reduced endothelial resistance significantly in comparison with HNA-3aa cells treated with anti-HNA-3b ( Figure 2A ).
Anti-HNA-3a Antibodies Induce Actin Polymerization, Vascular Endothelium-Cadherin Phosphorylation, and Dislocation in Endothelial Cells
Because actin and myosin in endothelial cells play a role in regulating paracellular endothelial permeability, 20 we examined the capability of anti-HNA-3a to modulate the actin cytoskeleton in HMVEC-L by immunocytochemistry. As shown in Figure 2B (top), anti-HNA-3a, but not anti-HNA-3b antibodies, induced extensive formation of actin stress filaments, comparable with the actin filament structure obtained after thrombin stimulation. Immunostaining of vascular endothelium (VE)-cadherin, the main adhesion molecule regulating endothelial junctions, showed loosening of VE-cadherin after treatment with anti-HNA-3a compared with anti-HNA-3b antibodies ( Figure 2B , bottom). Immunoblot analysis of VE-cadherin showed an increased VE-cadherin phosphorylation and degradation in anti-HNA-3a-treated and thrombintreated HMVEC-L compared with anti-HNA-3b-treated and untreated endothelial cells ( Figure 2C ). Previous studies have shown that VE-cadherin phosphorylation leads to uncoupling of p120 or β-catenin from the cytoplasmic tail of VE-cadherin and consequently to the disruption of cell-cell junctions, leading to increased endothelial permeability. 21, 22 
Anti-HNA-3a Antibodies Cause Increased Endothelial Permeability
To further explore the functional effect of anti-HNA-3a on endothelial barrier stability, albumin flux through HNA-3aa-positive endothelial cells treated with anti-HNA-3a antibodies was measured. As shown in Figure 3 , a significant increase in HMVEC-L and HUVEC monolayer permeability was detected after treatment with F(ab′) 2 fragments of anti-HNA-3a (derived from serum 11) compared with F(ab′) 2 fragments of anti-HNA-3b (derived from serum 14; Materials and Methods in the online-only Data Supplement). Thrombin was used as a positive control. Interestingly, we observed a gene-dose-dependent association between albumin flux and the HNA-3a phenotype of endothelial cells; homozygous HNA-3aa cells exhibited higher albumin flux compared with heterozygous HNA-3ab cells. This result accentuates an Fc-independent mechanism of endothelial permeability disturbance induced by anti-HNA-3a.
Similar results were obtained from 3 other anti-HNA-3a antibodies (derived from sera 3, 8, and 12; data not shown).
Anti-HNA-3a Antibodies Induce ROS Production in Endothelial Cells but Not Neutrophils
ROS derived from nicotinamide adenine dinucleotide phosphate oxidase in leukocytes and endothelial cells may impair the integrity of the endothelial barrier and may cause loss of cell-cell adhesion. [21] [22] [23] To decipher a direct capability of anti-HNA-3a antibodies to mediate lung dysfunction, neutrophil, as well as endothelial ROS production, was analyzed by 2′,7′-dichlorofluorescin diacetate staining. As shown in Figure 4A , treatment of neutrophils with anti-HNA-3a did not lead to ROS production in these cells. In contrast, HMVEC-L and HUVEC showed significant ROS production after treatment with anti-HNA-3a. In the control experiment, no ROS production was observed with anti-HNA-3b antibodies. To confirm these findings, neutrophils ROS production were re-evaluated by the use of the ferricytochrome-c reduction-based method. 24 As shown in Figure 4B , similar results were obtained. Again, the treatment of neutrophils with anti-HNA-3a IgG induced no significant ROS production, neither in quiescent nor in formyl-methionyl-leucyl phenylalanine post-treated neutrophils. In the control experiment, treatment with phorbol myristate acetate and formyl-methionyl-leucyl phenylalanine significantly induced neutrophil ROS production. Paraformaldehyde-fixed HNA-3aa-typed HMVEC-L or HUVEC were incubated with anti-HNA-3b (left) or anti-HNA-3a pAbs (right) and labeled with Texas red conjugated secondary antibodies (red). Endothelial platelets endothelial cells adhesion molecule 1 was visualized with mab Gi18 and FITC-labeled secondary antibodies (green). Labeled cells were analyzed by microscopy (×40).
Human Anti-HNA-3a Antibodies Bind to CTL2 Expressed on Murine Endothelial Cells
Alignment analysis of the CTL2 amino acid sequence between mouse (NM_152808.2) and man (NM_001145) reveals a high homology (84%) between these 2 species. 25 DNA sequencing of mouse primary lung endothelial cells predicts the presence of amino acid R154 that encodes the HNA-3a allele in men. 15 We, therefore, investigated whether human anti-HNA-3a antibodies can cross-react with CTL2 on murine endothelial cells. To exclude the presence of xenoantibodies in human sera, which may react with murine CTL2, anti-HNA-3a was purified by an adsorption/elution method using HNA-3a-transfected HEK cells (Materials and Methods in the online-only Data Supplement). Flow cytometry with mouse primary lung endothelial cell showed a positive reaction with purified human anti-HNA-3a, but not anti-HNA-3b antibodies, confirming the presence of the HNA-3a epitope on murine CTL2 ( Figure 5A ). This result could be further strengthened by immunocytochemistry analysis ( Figure 5B ) and immunoblotting ( Figure 5C ). To further investigate the functional consequences of anti-HNA-3a antibodies binding on mouse endothelial cells, a permeability test was performed. Exposure of mouse primary lung endothelial cell to purified anti-HNA-3a, but not anti-HNA-3b, antibodies significantly altered the endothelial integrity as shown by an increased influx of albumin ( Figure 5D ). All together, these observations introduce the possible application of a murine model to study the impact of human anti-HNA-3a antibodies on TRALI in vivo.
Infusion of Anti-HNA-3a Antibodies Induces TRALI in Mice
Because application of 800 µg total human IgG derived from 1-mL serum containing anti-HNA-3a antibodies to mice reproducibly induced TRALI, this dose of total human IgG (26.7 mg/kg) was used consistently in our in vivo experiments. This dose is in the lower physiological range because transfusion of a single unit of fresh-frozen plasma (350 mL) with an average IgG content (2450-5600 mg) to a 70-kg recipient represents an IgG dose of ≈35 to 80 mg/kg. 26 Lung edema as the hallmark of TRALI was assessed by measuring lung water content and was found to be increased dramatically in mice receiving anti-HNA-3a total IgG when compared with anti-HNA-3b-treated animals ( Figure 6A , left).
To further verify the specificity of TRALI in this mouse model, purified anti-HNA-3a and anti-HNA-3b antibodies (pAbs) were isolated by absorption-elution method (Materials and Methods in the online-only Data Supplement). The purity of the isolated IgG pAbs was confirmed by silver staining (data not shown), and pAbs concentration was measured by standardized solid phase ELISA. Injection of 200-µL (5.4 µg) HNA-3a pAb (0.18 mg/kg) purified from 1-mL serum induced TRALI with a comparable intensity, as did the infusion of total IgG obtained from an equal amount of serum.
Again, no significant increase of lung weight was measured with purified HNA-3b antibodies ( Figure 6A ). Interestingly, infusion of HNA-3a pAbs induced no significant difference between animals pretreated either with saline (−LPS) or with LPS (+LPS). However, infusion of total IgG in LPS pretreated mice resulted in a significant increase in lung water content when compared with non-LPS-treated animal.
Furthermore, we tested the ability of F(ab′) 2 antibody fragments to induce TRALI in our animal model. Application of anti-HNA-3a F(ab′) 2 fragment in a dose of 17.8 mg/kg (equal molarity compared with total IgG) induced specific increase of lung weight ( Figure 6A, left) . However, moderate TRALI was observed in F(ab′) 2 -treated animals when compared with total IgG.
In accordance with clinical observations of TRALI, arterial PO 2 decreased significantly in mice treated with different forms of anti-HNA-3a antibodies (Figure 6B, left) . Interestingly, a rapid drop of the core body temperature was detected in mice receiving anti-HNA-3a antibodies in all forms (Figure 6C, left) . This is in contrast to the observation in humans; patients with TRALI show rather fever than hypothermia. However, a core body temperature drop after inflammatory reactions has been observed in many mouse strains. 27, 28 Recently, hypothermia has been considered as an early indicator of TRALI in mice. 29 Further assessment of pulmonary edema by analysis of bronchoalveolar lavage revealed an increase in the neutrophil count and protein content ( Figure 6D and 6E, left). Interestingly, mice treated with F(ab′) 2 fragments recruited less numbers of neutrophils (P<0.01) in comparison with IgG-treated mice.
These results demonstrate that although human anti-HNA-3a antibodies are capable of inducing pulmonary edema in vivo via Fc-independent pathways, the Fc-part of endothelial-bound antibodies may still attract neutrophils through their Fcγ receptors, leading to recruitment, activation, and migration of neutrophils toward the alveolar space, which consequently worsens the effects of anti-HNA-3a antibodies on lung function.
Neutrophil Depletion Does Not Protect Mice From TRALI Induced by Anti-HNA-3a Antibodies
To examine the participation of neutrophils in HNA-3amediated TRALI, mice were depleted from their circulating were treated with anti-HNA-3a or anti-HNA-3b IgG (50 μg/mL). HNA-3aa-phenotyped resting neutrophils were treated with serum (10%) containing anti-HNA-3a or anti-HNA-3b antibodies. All cells were treated with phorbol myristate acetate (PMA) (320 nmol/L) as positive control. ROS produced in both cells were measured by flow cytometry using 2′,7′-dichlorofluorescin diacetate as fluorochrome. B, In vitro analysis of ROS production in quiescent and primed neutrophils. HNA-3aa-phenotyped neutrophils from healthy donors were isolated and were allowed to settle onto bovine serum albumin-coated microtiter wells for 30 minutes at 37°C. Subsequently, neutrophils were incubated with PBS or with IgG containing anti-HNA-3b or anti-HNA-3a antibodies (50 μg/mL) or formylmethionyl-leucyl phenylalanine (fMLF) (1 μmol/L) or PMA (100 nmol/L) as positive control (n=5). In some experiments, neutrophil incubation with IgG containing anti-HNA-3b or anti-HNA-3a antibodies was followed by fMLF stimulation (1 μmol/L). The release of superoxide anions was conducted for 100 minutes using 50 μmol/L ferricytchrom C. Blanks consisting of ferricytochrome-c and superoxide dismutase (SOD; 300 U/mL) were run in parallel. Absorption of samples in the presence and absence of SOD at 550 nm was repetitively measured using Tecan microtitre plate reader. All data are presented as mean of 5 independent experiments (mean±SD). neutrophils using mab Gr-1. 27 Twenty-four hours after antibody injection, circulating neutrophils were monitored by flow cytometry (data not shown). Neutrophil-depleted mice were then infused with anti-HNA-3a IgG as described before. All neutrophil-depleted animals developed signs of TRALI, including increased lung water content, drop in arterial PO 2 and body temperature, and increased protein content in bronchoalveolar lavage fluid ( Figure 6A -6C and 6E, right). Of note, TRALI signs in neutrophil-depleted mice were moderate when compared with nondepleted mice (Figure 6A , right).
NOX2 y/− Mice Are Protected From Anti-HNA-3a-Mediated TRALI
To confirm the role of endothelial ROS-dependent effects of anti-HNA-3a antibodies on barrier function as observed in vitro, we analyzed the capability of anti-HNA-3a to induce TRALI in NOX2-deficient mice (NOX2 y/− ). Infusion of anti-HNA-3a antibodies in these mice did not cause any significant changes in lung water, arterial PO 2 , body temperature, or composition of bronchoalveolar lavage fluid, when compared with controls ( Figure 6A-6E, right) . These results indicate that anti-HNA-3a antibodies may alter the endothelial barrier integrity mainly via endothelial cell-derived ROS.
Infusion of Anti-HNA-3a Antibodies Enhances ROS Production Abilities of Neutrophils
To determine whether anti-HNA-3a antibodies can modulate respiratory burst activity of neutrophils in vivo, ROS production in neutrophils isolated from mice challenged with anti-HNA-3a or anti-HNA-3b antibodies was assessed. Interestingly, ROS production was enhanced in mice treated with anti-HNA-3a antibodies when compared with neutrophils isolated from anti-HNA-3b antibody-treated mice (Figure 7) . Similar effects were observed when isolated neutrophils were further treated with phorbol myristate acetate.
Discussion
Although some studies have reported anti-HNA-3a antibodies against CTL2 as the most leading cause for fatal reactions in antibody-mediated TRALI, 11 the exact mechanism how these antibodies induce lung dysfunction is unclear. 30, 31 Previous reports have documented that ligation of HLA class I antigens on endothelial cells by anti-HLA class I antibodies triggers different cellular events (cell apoptosis or proliferation). 19, 32 Recently, our group has shown an important role for ROS in inducing endothelial dysfunction after antibody binding (anti-non-structural glycoprotein-1). 33 More recently, Strait et al 34 have given preliminary evidence that non-bone marrow-derived cells, most likely the pulmonary vascular endothelium, seem to play a crucial role in TRALI induced by antibodies against major histocompatibility complex (MHC) class I. Taking advantage of the cross-reactivity between human anti-HNA-3a antibodies and murine CTL2, we were able to demonstrate that (1) antibody binding to pulmonary vascular endothelium can directly affect barrier integrity leading to lung edema; (2) these effects are not Fc dependent; (3) production of ROS in the endothelium is a critical event in this pathway by inducing VE-cadherin removal from the endothelial junction; and (4) neutrophils seem not to be an initiator in anti-HNA-3a-mediated TRALI; however, their presence may aggravate the destructive effects of anti-HNA-3a.
A wide expression of CTL2 in different tissues, such as lung, heart, colon, kidney, liver, and spleen, has been reported. 17 Among these tissues, lungs possess abundant amounts of CTL2 transcripts encoding for 2 different isoforms, CTL2-P1 and CTL2-P2. 35 Whereas the CTL2-P2 isoform exhibits choline transport activity, no function has been described for CTL2-P1 to date. 17, 18 In our study, we could identify that human lung endothelial cells express both CTL2 isoforms, whereas neutrophils carry CTL2-P1 only. Both isoforms react with anti-HNA-3a as shown by our analysis with transfected cells. Thus, in contrast to neutrophils, anti-HNA-3a recognizes the functional active form of CTL2 on endothelial cells. Accordingly, we observed a direct effect of anti-HNA-3a on endothelial cells function(s) in vitro. Treatment of HNA-3a-positive endothelial cells with IgG containing anti-HNA-3a antibodies caused ROS production, increased endothelial permeability, a drop of endothelial resistance associated with the formation of actin stress fibers, and finally degradation of VE-cadherin from endothelial adherent junctions. These effects were Fc independent; F(ab′) 2 fragments of anti-HNA-3a antibodies were able to provoke similar endothelial barrier dysfunction.
Several studies introduced the application of mabs to induce TRALI in vivo. 27, 29, 36, 37 Our preliminary experiments showed no reactivity of available mabs against CTL2 (F7; Santa Cruz and 3D11; Abnova), neither on neutrophils nor on endothelial cells (data not shown). Fortunately, we discovered that human anti-HNA-3a shows cross-reactivity with primary mouse lung endothelial cells. Stimulation of these cells with human anti-HNA-3a led to increased endothelial permeability, an effect comparable with human endothelial cells. This observation disclosed the first possibility to analyze human neutrophil antibodies in an animal model, closely mimicking the clinical situation of antibody-mediated TRALI. Using this model, we could demonstrate that the injection of Figure 6 . Analysis of lung function after in vivo treatment with anti-HNA-3a or anti-HNA-3b antibodies in wild-type (left), neutrophildepleted mice and NOX2 y/− mice (right). C57BL/6J mice (wild type) were injected with total IgG (26.7 mg/kg; n=10) or purified antibodies (pAbs; 0.18 mg/kg; n=5) or F(ab′)2 fraction (17.8 mg/kg; n=3) isolated from serum containing anti-HNA-3b (white columns) or anti-HNA-3a antibodies (gray columns) in the absence (n=4) and in the presence (n=4) of lipopolysaccharides (LPS) (left). Animals were euthanized 2 hours (IgG and F(ab′')2) or 20 minutes (pAb) after the antibody infusion. In a separate set of experiments (right), neutrophils were depleted from the blood circulation of LPS-treated wild-type mice (n=10) before injection of total IgG (26.7 mg/kg) and LPS-treated NOX2 y/− -deficient mice (n=10) were treated with total IgG under same conditions. Lung water content (A), arterial oxygen pressure (B), Δ body temprature (C), percentage of neutrophils in total cells (D), and protein concentration (E) in bronchoalveolar lavage in all treated mice were measured. Data were analyzed statistically by unpaired t test for comparison of anti-HNA-3a and anti-HNA-3b antibody-treated groups. All data are presented as mean±SD of independent experiments; ***P<0.0001, **P<0.001, *P<0.01. n.d indicates not detected; and n.s, nonsignificant.
physiological doses of IgG purified from anti-HNA-3a containing sera induced TRALI in C57BL/6J mice evidenced by increase of lung water content, neutrophil numbers, and protein content in bronchoalveolar lavage fluid. To further verify the specificity of TRALI in these mice, purified anti-HNA-3a was isolated by an absorption/elution method. Injection of these purified antibodies caused similar TRALI intensity as observed with total IgG. However, mice treated with purified anti-HNA-3a antibodies developed TRALI more rapidly (20 minutes versus 2 hours). Of note, the amount of HNA-3a pAbs (0.18 mg/kg) used in this study was 45% of the mab (4 mg/kg) used in previous animal models of anti-HLA class I-mediated TRALI. 27, 29, 37, 38 Besides the amount of transfused neutrophil-reactive antibodies, preinflammatory conditions of recipients are known as potential factor enhancing TRALI precipitation (threshold model). 8, 38, 39 Kopko et al 40 have shown that transfusion of fresh-frozen plasma containing anti-HNA-3a to patients carrying the cognate antigen is not always associated with TRALI in the recipient. However, transfused plasma volume and clinical background of the patient, 2 important factors known to influence the fate of antibody-positive transfusions, are unavailable in this study. Others documented that anti-HNA-3a antibodies could initiate TRALI in the absence of inflammatory conditions. 41, 42 In accordance with the latter observation, we were able to induce anti-HNA-3a-mediated TRALI in LPS nontreated mice. However, pretreatment with LPS before injection aggravated TRALI in these animals. This observation underlines the fact that differences in the underlying disease and amount/volume of transfused antibodies may modify the overall result. 43 The nicotinamide adenine dinucleotide phosphate oxidase (NOX) family is dedicated to generate relatively large amounts of ROS. One NOX member, NOX2, shows wide expression in different cells, including endothelial cells and neutrophils 44 ; overactivity of NOX2 is associated with tissue damage. 45 Recently, one of us demonstrated that ROS generated via NOX2 in endothelial cells, but not neutrophils, plays an important role in the mechanism of lung injury induced by ischemia-reperfusion. 46 Notably, we were unable to induce TRALI by the infusion of anti-HNA-3a into NOX2-deficient mice. This observation indicates that endothelial ROS is an important trigger for the induction of endothelial dysfunction in TRALI mediated by anti-HNA-3a antibodies.
Several studies have documented that ROS produced in endothelial cells could trigger VE-cadherin degradation leading to endothelial barrier break down. 21, 22, 47 Accordingly, our in vitro analysis showed that treatment of endothelial cells with anti-HNA-3a increased VE-cadherin phosphorylation and subsequently VE-cadherin degradation. ROS produced in endothelial cells may induce apoptotic stimuli and, therefore, may impair endothelial barrier function. 48 We were able to demonstrate barrier breakdown in different experimental settings, but were unable to demonstrate apoptotic cell death after application of anti-HNA-3a (data not shown); we thus believe that anti-HNA-3a-induced TRALI is primarily mediated via breakdown of interendothelial junctions.
In addition, endothelial ROS production is known to be involved in the destabilization of the endothelial barrier through von Willebrand Factor secretion. 49, 50 This process may aggravate theoretically TRALI by supporting neutrophil recruitment toward activated endothelial cells.
Previous studies demonstrated that dysfunction of CTL family members could cause choline deficiency that initiates transforming growth factor β1 signaling and affects the expression of genes involved in cell proliferation, differentiation, and cell apoptosis. 51 In addition, induction of transforming growth factor β1 signaling pathway is known to be responsible for the generation of ROS in endothelial cells. 52 Accordingly, binding of anti-HNA-3a to the functional CTL2-P2 isoform, expressed on endothelial cells, may initiate signal transduction leading to ROS production. This intriguing hypothesis is the subject matter of our future work.
Our study also unraveled that anti-HNA-3a binding to endothelial cells, but not neutrophils, induces endothelial ROS production. It has been demonstrated previously that direct exposure of resting neutrophils to anti-HNA-3a alone is not sufficient to induce ROS. 12, 13 However, ROS was detectable in anti-HNA-3a IgG-primed neutrophils followed by formyl-methionyl-leucyl phenylalanine stimulation. 13 In contrast to this report, we did not observe a significantly augmented respiratory burst reaction neither in resting nor in formyl-methionyl-leucyl phenylalanine-treated neutrophils primed with anti-HNA-3a antibodies using 2 different methods (2′,7′-dichlorofluorescin diacetate and ferricytochromec). Different antibody concentrations in sera or different binding sites (epitopes) recognized by polyclonal antibodies may explain partially the discrepancy of these results. Our ex vivo experiments, however, showed enhanced ROS production in neutrophils isolated from mice which experienced anti-HNA-3a-mediated TRALI. Thus, the presence of anti-HNA-3a in the systemic blood circulation may lead to neutrophil priming in vivo, most likely via an indirect mechanism (such as interaction with the endothelium), and may enhance deleterious effects of antibody on endothelial function.
In an in vivo TRALI model, Looney et al 27 showed a significant role of FcγR on neutrophils in anti-MHC I-mediated TRALI; FcγR defective mice or neutrophil-depleted mice were protected from TRALI induced by mab anti-H2K d (34-1-2S) against monomorphic epitopes on the MHC I antigen.
These results indicate that cross-linking between neutrophils with other cells, for example, endothelial cells, is crucial in TRALI. Although, antibody concentration assigned in this study was very high. The relevance of this finding has recently been questioned. 34 In addition, Kelher et al 53 have demonstrated that MHC class I antibodies can bind to the neutrophil surface and, via neutrophil activation, lead to acute lung injury in rats. In our study, TRALI precipitated in neutrophil-depleted mice when treated with total IgG containing anti-HNA-3a. Even more, infusion of anti-HNA-3a F(ab′) 2 fragments (equal molarity) efficiently induced TRALI in the model. This observation is in accordance with our in vitro experiment demonstrating that anti-HNA-3a F(ab′) 2 fragments alone were able to alter endothelial permeability. It should be mentioned, however, that a significant decrease in TRALI intensity was observed in mice infused with F(ab′) 2 fragments in comparison with those infused with total IgG. This observation may indicate the existence of additional Fc-dependent mechanism(s), such as reinforcing neutrophil recruitment toward the endothelium; note that in our model, the number of neutrophils recruited was significantly decreased in F(ab′) 2 -treated mice. Thus, cross-linking between different cells expressing HNA-3a antigens seems to resemble an important factor for the severe effects of anti-HNA-3a-mediated TRALI. In this regard, the role of monocytes on the mechanism of TRALI demands further investigation. 34, 42 It is well known that anti-HNA-3a antibodies form strong neutrophil agglutinates in some in vitro assays, such as the GAT assay. Recently, Greinacher et al 12 demonstrated that this mechanism is FcγR independent. The question whether this phenomenon occurs in vivo and participates in the mechanism of TRALI is not clear. In autopsy samples of 2 patients who died secondary to anti-HNA-3a-induced TRALI, neutrophil congestion in alveolar capillaries has been reported. 54 However, additional neutrophil reactive antibodies (anti-HLA class I and II antibodies) have been identified in these blood products. In an ex vivo anti-HNA-3a-mediated TRALI model, Seeger et al 41 calculated that the amount of neutrophils used in their experiments would not be sufficient to occlude a relevant percentage of the large lung microvascular bed and concluded that neutrophil activation rather than neutrophil agglutination caused lung edema. In this model, however, the possible direct interaction of anti-HNA-3a antibodies with rabbit lung endothelial cells was not investigated. This is in line with our recent observation. Although we were able to precipitate TRALI in our model in the absence of neutrophils, a reduction of TRALI severity was observed in neutrophil-depleted mice. A similar reduction was found in mice treated with F(ab′) 2 fragments. This observation indicates that neutrophil activation mediated by FcγR crosslinking can aggravate endothelial dysfunction, but pulmonary endothelial cells are most likely the major targets in anti-HNA-3a-induced TRALI. Interestingly, our observation is in accordance with a previously unraveled mechanism by Strait et al, 34 who indicated a crucial role of non-bone-marrowderived cells in MHC class I antibody-mediated TRALIand speculated that pulmonary endothelial cells are likely to represent these players.
In conclusion, we demonstrate that human anti-HNA-3a antibodies mediated severe TRALI via direct interaction with endothelial CTL2 that leads to pulmonary endothelial barrier disturbance triggered by increased ROS generation and VE-cadherin degradation in these cells. Endothelial dysfunction followed by neutrophil recruitment and activation further augments the destructive effects. Notably, on the basis of wide expression of CTL2, we found that the other cells may be involved in antibody-mediated effects in vivo. Inhibition of this pathway by substances that strengthen endothelial integrity, such as adrenomedullin, 55 would be an interesting, new approach in treating severe antibody-mediated TRALI.
